Karyopharm Therapeutics (Karyopharm Therapeutics) FCF Margin % : -55.07% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Karyopharm Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-18.6 Mil. Karyopharm Therapeutics's Revenue for the three months ended in Dec. 2023 was $33.7 Mil. Therefore, Karyopharm Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -55.07%.

As of today, Karyopharm Therapeutics's current FCF Yield % is -75.11%.

The historical rank and industry rank for Karyopharm Therapeutics's FCF Margin % or its related term are showing as below:

KPTI' s FCF Margin % Range Over the Past 10 Years
Min: -54844.81 Med: -499.72 Max: -53.77
Current: -63.49

During the past 13 years, the highest FCF Margin % of Karyopharm Therapeutics was -53.77%. The lowest was -54844.81%. And the median was -499.72%.

KPTI's FCF Margin % is ranked better than
58.9% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs KPTI: -63.49

Karyopharm Therapeutics FCF Margin % Historical Data

The historical data trend for Karyopharm Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics FCF Margin % Chart

Karyopharm Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-467.14

-148.38

-53.77

-95.29

-63.49

Karyopharm Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-79.94	-48.87	-68.38	-82.01	-55.07

Competitive Comparison of Karyopharm Therapeutics's FCF Margin %

For the Biotechnology subindustry, Karyopharm Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karyopharm Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's FCF Margin % falls into.

Karyopharm Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Karyopharm Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-92.723	/	146.033
	=	-63.49 %

Karyopharm Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-18.585	/	33.747
	=	-55.07 %

Karyopharm Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics (Karyopharm Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

25K:Germany 25K:Germany

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Executives

Richard A. Paulson	director, officer: President and CEO	85 WELLS AVENUE, NEWTON MA 02459
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Michael Mason	officer: EVP, CFO, Treasurer	300 3RD STREET, CAMBRIDGE MA 02142
Michael Mano	officer: SVP, General Counsel&Secretary	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng	officer: SVP Sales & Commercial Ops	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Zhen Su	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stuart Poulton	officer: EVP, Chief Development Officer	85 WELLS AVENUE, NEWTON MA 02459
Reshma Rangwala	officer: EVP & Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Stephen Mitchener	officer: SVP, Chief Business Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Ran Frenkel	officer: EVP, WW Development Operations	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah	officer: EVP, Chief Medical Officer	C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham	officer: C.S.O & Pres. of Res & Develop	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman	director, officer: President, C.E.O., C.M.O.	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037